Cytomegalovirus retinitis in the era of highly active antiretroviral therapy

JAMA

Volumn 283, Issue 5, 2000, Pages 653-657

  Whitcup, Scott M ^a,b  

^a NATIONAL EYE INSTITUTE   (United States)

^b ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; FOSCARNET SODIUM; GANCICLOVIR; RITONAVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CASE REPORT; CATARACT; CYTOMEGALOVIRUS INFECTION; EPIRETINAL MEMBRANE; EYE INFLAMMATION; HUMAN; LYMPHOCYTE COUNT; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; RETINITIS; UVEITIS; VIRUS LOAD; VISUAL ACUITY;

EID: 0034594634     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.5.653     Document Type: Article

References (40)

1. Whitcup SM, Fortin E, Nussenblatt RB, Polis MA, Muccioli C, Belfort RJ. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis. JAMA. 1997;277:1519-1520.
2. + counts. Ophthalmology. 1998;105:1259-1264.
3. Whitcup SM, Cunningham ET Jr, Polis MA, Fortin E. Spontaneous and sustained resolution of CMV retinitis in patients receiving highly active antiretroviral therapy. Br J Ophthalmol. 1998;82:845-846.
4. Whitcup SM, Fortin E, Lindblad AS, et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA. 1999;282:1633-1637.
5. Whitcup SM, Robinson MR, Csaky KG. Visual morbidity with immune recovery uveitis in patients with cytomegalovirus retinitis. Invest Ophthalmol Vis Sci. 1999;40:S189.
6. Freeman WR, Lerner CW, Mines JA, et al. A prospective study of the ophthalmologic findings in the acquired immunodeficiency syndrome. Am J Ophthalmol. 1984;97:133-142.
7. Palestine AG, Polis MA, De Smet MA, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med. 1991;115:665-673.
8. Schuman JS, Friedman AH. Retinal manifestations of the acquired immune deficiency syndrome. Trans Ophthalmol Soc UK. 1983;103:177-189.
9. Pepose JS. Ophthalmic manifestations of HIV infection. Curr Top AIDS. 1989;2:191-206.
10. + counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol. 1993;115:575-582.
11. Holland GN, Shuler JD. Progression rates of CMV retinopathy in ganciclovir-treated and untreated patients. Arch Ophthalmol. 1992;110:1435-1442.
12. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med. 1992;326:213-220.
13. Jacobson MA, O'Donnell JJ, Porteous D, Brodie HR, Feigal D, Mills J. Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome: prevalence, natural history, and response to ganciclovir therapy. QJM. 1988;67:473-486.
14. Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS: a randomized, controlled trial. Ann Intern Med. 1997;126:257-263.
15. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial: a randomized, controlled trial. Ann Intern Med. 1997;126:264-274.
16. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science. 1997;276: 960-963.
17. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387:188-191.
18. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
19. Jabs DA, Bartlett JG. AIDS and ophthalmology: a period of transition. Am J Ophthalmol. 1997;124: 227-233.
20. Reed JB, Schwab IR, Gordon J, Morse LS. Regression of cytomegalovirus retinitis associated with protease inhibitor treatment in patients with AIDS. Am J Ophthalmol. 1997;124:199-205.
21. Tural C, Romeu J, Siera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis. 1998;177:1080-1083.
22. Macdonald JC, Torriani FJ, Morse LS, Karavellas MP, Red JB, Freeman WR. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis. 1998;177:1182-1187.
23. Jabs DA, Bolton SG, Dunn JP, Palestine AG. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmol. 1998;126:817-822.
24. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet. 1997;349:1443-1445.
25. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med. 1997;3:533-540.
26. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group protocol 315. J Infect Dis. 1998;178:70-79.
27. + T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med. 1998;4:953-956.
28. Palestine AG, Rodrigues MM, Macher AM, et al. Ophthalmic involvement in acquired immunodeficiency syndrome. Ophthalmology. 1984;91:1092-1099.
29. Zegans ME, Walton RC, Holland GN, O'Donnell JJ, Jacobson MA, Margolis TP. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol. 1998;125: 292-300.
30. Karavellas MP, Lowder CY, Macdonald JC, Avila CP, Freeman WR. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. Arch Ophthalmol 1998;116:169-175.
31. Weinberg DV, Moorthy RS. Cystoid macularedema due to cytomegalovirus in a patient with acquired immunodeficiency virus. Retina. 1996;16:1443-1445.
32. Karavellas MP, Plummer DJ, Macdonald JC, et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis. 1999;179:697-700.
33. Henderson HW, Mitchell SM. Treatment of immune recovery vitritis with local steroids. Br J Ophthalmol. 1999;83:540-545.
34. Magone TM, Nussenblatt RB, Whitcup SM. Elevation of laser flare photometry in patients with cytomegalovirus retinitis and AIDS. Am J Ophthalmol. 1997;124:190-198.
35. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Künndig T, Hengartner H. Antigen localisation regulates immune responses in a dose-and time-dependent fashions geographical view of immune reactivity. Immunol Rev. 1997;156:199-209.
36. Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet. 1998;351:252-255.
37. Woods ML, MacGinley R, Eisen DP, Allworth AM. HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection. AIDS. 1998; 12:1491-1494.
38. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized, controlled clinical trial. Arch Ophthalmol. 1994;112: 1531-1539.
39. Feinberg MB, Carpenter C, Fauci AS, et al. Report of the NIH panel to define principles of therapy of HIV infection. Ann Intern Med. 1998;128:1057-1078.
40. Centers for Disease Control and Prevention. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1999;48:1-66.